AU Patent

AU2007290099B2 — Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor

Assigned to Actelion Pharmaceuticals Ltd · Expires 2013-01-31 · 13y expired

What this patent protects

The invention relates to a product containing the compound of formula (I) below (I) or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5 -inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic…

USPTO Abstract

The invention relates to a product containing the compound of formula (I) below (I) or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5 -inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved.

Drugs covered by this patent

Patent Metadata

Patent number
AU2007290099B2
Jurisdiction
AU
Classification
—
Expires
2013-01-31
Drug substance claim
No
Drug product claim
No
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.